extrapyramidal side effects

Eticlopride, an antipsychotic, is a Selective dopamine D2/D3 receptor antagonist (Ki: 0.5/0.16 nM).

Blonanserin (AD-5423) is an atypical antipsychotic approved in Japan in January, 2008. Relative to many other antipsychotics, blonanserin has an improved tolerability profile, lacking side effects such as extrapyramidal symptoms, excessive sedation, or hypotension.

Preclamol hydrochloride ((-)-3-PPP hydrochloride) is a selective dopamine autoreceptor agonist. It functions by specifically activating presynaptic autoreceptors, which triggers a negative feedback loop to inhibit the synthesis and release of dopamine. Unlike conventional neuroleptics that primarily block postsynaptic receptors, Preclamol offers a more refined modulation of the dopaminergic system. This unique pharmacological profile makes it a valuable tool in schizophrenia research, aiming to alleviate psychotic symptoms with a potentially lower risk of extrapyramidal side effects.

Blonanserin-D5 is a deuterated compound of Blonanserin. Blonanserin (T1180) has a CAS number of 132810-10-7. Blonanserin (T1180) is an atypical antipsychotic approved in Japan in January, 2008. Relative to many other antipsychotics, blonanserin has an improved tolerability profile, lacking side effects such as extrapyramidal symptoms, excessive sedation, or hypotension.

Blonanserin (Standard) is a reference standard for research and analysis in studies involving Blonanserin. Blonanserin (AD-5423) is an atypical antipsychotic approved in Japan in January, 2008. Relative to many other antipsychotics, blonanserin has an improved tolerability profile, lacking side effects such as extrapyramidal symptoms, excessive sedation, or hypotension.